anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Radical cystectomy (RC) is the gold standard treatment for patients with organ-confined bladder cancer. However, despite the success of this treatment, many men who undergo orthotopic neobladder substitution develop significant erectile dysfunction and urinary symptoms, including daytime and nighttime urinary incontinence. Prostate-capsule-sparing radical cystectomy (PCS-RC) with orthotopic neobladder (ONB) has been described in the literature as a surgical technique to improve functional outcomes in appropriately selected patients. We performed a systematic review and meta-analysis of manuscripts on PCS-RC with ONB published after 2000. We included retrospective and prospective studies with more than 25 patients and compared PCS-RC with nerve-sparing or conventional RC. Studies in which the entire prostate was spared (including the transitional zone) were excluded. Comparative studies were analyzed to assess rates of daytime continence, nighttime continence, and satisfactory erectile function in patients undergoing PCS-RC compared with those undergoing conventional RC. Fourteen reports were included in the final review. Our data identify high rates of daytime (83%-97%) and nighttime continence (60%-80%) in patients undergoing PCS-RC with ONB. In comparative studies, meta-analysis results demonstrate no difference in daytime continence (RR:1.12; 95% CI: 0.72-1.73) in those undergoing PCS-RC compared to those undergoing conventional RC. Similarly, nighttime continence was similar between the 2 groups (RR:1.85; 95% CI: 0.57-6.00. Erectile function was improved in those undergoing PCS-RC (RR 5.35; 95% CI: 1.82-15.74) in the PCS-RC series. Bladder cancer margin positivity and recurrence rates were similar to those reported in the literature with conventional RC with an average weighted follow-up of 52.2 months. While several studies utilized different prostate cancer (CaP) screening techniques, the rates of CaP were low (incidence 0.02; 95% CI:0.01-0.04), and oncologic outcomes were similar to standard RC. PCS-RC is associated with improved nighttime continence and erectile function compared to conventional RC techniques. Further work is needed to standardize CaP screening before surgery, but the data suggest low rates of CaP with similar oncologic outcomes when compared to RC.
The invention relates to the technical field of health-care food, in particular to a composition with functions of clearing damp, expelling toxin and relieving summer heat and a preparation method thereof. The composition comprises the following components in parts by weight: 15-50 parts of rhubarb stem, 10-40 parts of black wolfberry, 8-30 parts of snow chrysanthemum, 8-30 parts of mint and/or the balance of auxiliary materials. The rhubarb stem, the lycium ruthenicum murr, the snow chrysanthemum and the mint in the product belong to raw materials with higher nutritional value and medicinal value, the beneficial components in the raw materials can be mutually cooperated and are easy to extract, and the product has the functions of expelling toxin, relieving summer heat, clearing fire and removing dampness after being drunk. Also has effects in improving body function, improving sub-health state, enhancing immunity, and improving metabolism. Is suitable for 75% of sub-health people. The active ingredients of the components are retained to the maximum extent by the processes of selection, soaking, centrifugation, filtration, homogenization and the like and by the advanced homogenization, membrane filtration and sterilization technologies. The herbal tea can be processed into herbal tea, and can be widely used in the fields of food, health products and medicines.
Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. On Day 14 after CAR-T, eligible patients will be given NKTR-255 IV over 30 minutes, and it will be repeated every 28 days for up to 6 cycles. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
FIELD: medicine. SUBSTANCE: adhesive plaster bandage, wound bandage, suture or surgical sheet intended for covering wound are made from flexible rubber of laminated structure, hydrophylic hydrogel polymer bound to one side of flexible rubber, and adhesive substance bound with hydrophylic hydrogel polymer, at least, on the first section of adhesive plaster bandage, wound bandage, suture or surgical sheet. Adhesive substance is used in the form of hydrogel adhesive substance with cellulose, polyurethane or polyacrylate base. Flexible rubber is used, preferably, in the form of rubber which is preliminarily treated with hydrogel polymer prior to use. Medicament of pyridinchlorocetyl or ammonium benzyl type may be bound with hydrophylic hydrogel polymer on plaster bandage part having no adhesive, wound bandage or surgical sheet to provide for slow liberation of medicament, and, if required, adhesive parts may be covered with removed plastic. In one version of embodiment, adhesive plaster bandage 10 is a laminated material consisting of flexible elastomer 15 whose one side is bound with hydrogel polymer coating 20. Adhesive 25 is bound with at least some sections of hydrogel polymer coating 20. EFFECT: higher efficiency. 1 dwg
OBJECTIVE: Lumbar disc herniation (LDH) is rare in young adults. The present study aimed to evaluate the clinical outcomes of full-endoscopic lumbar discectomy (FELD) for LDH in young adults and to determine the risk factors that predict unfavorable outcomes of FELD for LDH in young adults.
METHODS: A retrospective two-center cohort study was performed between January 2015 and October 2021 at the authors' institutions. Clinical outcomes were assessed using the visual analog scale (VAS) for low-back pain and leg pain and the Oswestry Disability Index (ODI). The modified Macnab criteria were used to evaluate clinical efficacy at the last follow-up, and the global outcomes were classified into 4 groups, namely excellent, good, fair, and poor. The fair and poor groups were defined as unfavorable outcomes.
RESULTS: One hundred ninety-nine patients were analyzed in this study (mean age 18.5 years, mean BMI 25.1 kg/m2, male/female sex ratio 2.8). The duration from the onset of symptoms to the operation was in general prolonged with age. The VAS and ODI scores significantly improved after surgery. A total of 17 of 195 single-segment cases had unfavorable outcomes based on the modified Macnab criteria. Lateral disc herniation (OR 3.72, 95% CI 1.14-12.12, p = 0.029) and high preoperative VAS score (OR 1.98, 95% CI 1.13-3.46, p = 0.017) were identified as risk factors for unfavorable outcomes after FELD.
CONCLUSIONS: FELD for LDH in young adults is safe and effective. Preoperative VAS score and lateral disc herniation are risk factors of nonfavorable outcomes after surgery and may be a useful index for surgical procedure selection.
Dopaminergic agonists, in clinical studies and clinical experience, appear to impair the systemic regulation of blood pressure, resulting in postural/orthostatic hypotension, especially during dose escalation. Parkinson's disease patients, in addition, appear to have an impaired capacity to respond to a postural challenge. For these reasons, both Parkinson's and Restless Legs Syndrome patients being treated with dopaminergic agonists ordinarily (1) require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and (2) should be informed of this risk.

An increased risk for decreases in systolic and diastolic blood pressure were observed when supine, standing, and changing from supine to standing position in patients treated with NEUPRO. In patients taking the maximum recommended NEUPRO dose, orthostatic (change from supine to standing) decreases in systolic blood pressure (at least 20 mm Hg or greater) was 16% for NEUPRO and 14% for placebo in patients with early-stage Parkinson's disease, 32% for NEUPRO and 27% for placebo in patients with advanced-stage Parkinson's disease, and 13% for NEUPRO and 11% for placebo in patients with Restless Legs Syndrome.

More severe decreases in systolic blood pressure (40 mm Hg or greater) and in diastolic blood pressure (20 mm Hg or greater) also occurred more frequently (NEUPRO incidence at least 2% greater than placebo) in patients with early- and advanced-stage Parkinson's disease during measurements when supine, standing, or changing from supine to standing position. Patients experienced dose-related decreases in blood pressure at different times throughout the trial including the final visit.

An analysis using a variety of adverse reaction terms suggestive of orthostatic hypotension, including dizziness/postural dizziness and others, showed an increased risk for all patients treated with NEUPRO. For the maximum recommended NEUPRO dose, the incidence of adverse reactions suggestive of hypotension/orthostatic hypotension was 29% for NEUPRO and 11% for placebo in early-stage Parkinson's disease, 27% for NEUPRO and 23% for placebo in advanced-stage Parkinson's disease, and 8% for NEUPRO and 7% for placebo in Restless Legs Syndrome.

This increased risk for symptomatic hypotension and decreases in blood pressure was observed in a setting in which patients were very carefully titrated, and patients with clinically relevant cardiovascular disease or symptomatic orthostatic hypotension at baseline had been excluded from this study. The increased risk for significant decreases in blood pressure or orthostatic hypotension occurred especially in the dose escalation/titration period.
A smart mat system is provided for performing exercises herein. The smart mat system may include an exercise mat. The exercise mat may include sensors configured for sensing objects. The sensors may transmit sensor information to a mobile component. The mobile component may determine a user's balance, weight distribution, and correctness of a pose. The mobile component may store historic data associated with the user's exercises.
Described herein are biphasic compositions for topical administration, to relieve pruritis. The pruritis may be associated with insect bites, rash, cuts or bums. The compositions comprise a cannabinoid and at least one anesthetic agent. The compositions are biphasic compositions comprising an aqueous phase and an oil-based phase. The two phases may be contained in a single container and mixed, for example, by shaking, before administration of the composition to the skin of the patient. Additionally described herein are methods for treating pruritis comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid and at least one anesthetic ingredient.
* Take one PREMARIN tablet at the same time each day.
  * If you miss a dose, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your normal schedule. Do not take 2 doses at the same time.
  * Estrogens should be used at the lowest dose possible for your treatment only as long as needed. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with PREMARIN.
Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
BACKGROUND: Among the various diaphragm-sparing alternatives to interscalene block, costoclavicular block (CCB) demonstrated a low hemidiaphragmatic paresis (HDP) occurrence but an inconsistent analgesic effect in arthroscopic shoulder surgery. We hypothesized that a larger volume of local anesthetic for CCB could provide sufficient analgesia by achieving sufficient supraclavicular spreading.
METHODS: Sixty patients scheduled for arthroscopic rotator cuff repair were randomly assigned to receive CCB using one of two volumes of local anesthetic (CCB20, 0.75% ropivacaine 20 ml; CCB40, 0.375% ropivacaine 40 ml). The primary outcome was the rate of complete analgesia (0 on the numeric rating scale of pain) at 1 h postoperatively. The secondary outcomes included a sonographic assessment of local anesthetic spread, diaphragmatic function, pulmonary function, postoperative opioid use, and other pain-related experiences within 24 h postoperatively.
RESULTS: The rates of complete analgesia were not significantly different (23.3% [7/30] and 33.3% [10/30] in the CCB20 and CCB40 groups, respectively; risk difference 10%, 95% CI [-13, 32], P = 0.567). There were no significant differences in other pain-related outcomes. Among the clinical factors considered, the only factor significantly associated with postoperative pain was the sonographic observation of supraclavicular spreading. There were no significant differences in the incidence of HDP and the change in pulmonary function between the two groups.
CONCLUSIONS: Using 40 ml of local anesthetic does not guarantee supraclavicular spread during CCB. Moreover, it does not result in a higher rate of complete analgesia compared to using 20 ml of local anesthetic in arthroscopic shoulder surgery.
The profiles of intensive care cnit (ICU) critically ill inpatients differ from those of other hospitalized patients, since organ dysfunction is a factor that increases the risk for Refeeding Syndrome (RS) development. It is important to understand the influence of feeding methods and caloric intake on mortality and RS incidence among critically ill adult inpatients. A systematic search, following PRISMA guidelines and protocol for systematic reviews, was conducted for interventional and experimental studies analyzing RS occurrence in adults admitted to ICUs. Pubmed, Scielo, Lilacs, Google Scholar, Scopus and Web of Science were the databases searched, and the Scottish Intercollegiate Guidelines Network (SIGN) tool was used to assess methodological quality of selected articles. Out of 945 abstracts screened, 32 articles were read in full and 20 were included for data extraction. Considerable heterogeneity was found between all studies reviewed. Enteral feeding was the most used method, and, in general, progression of caloric intake did not follow the American Society of Parenteral and Enteral Nutrition (ASPEN) or National Institute of Health and Care (NICE) recommendations for RS. In majority, data collection period of studies was less than 7 days; RS was observed in up to 52.5% of patients, and related mortality varied between 15.6 and 83.3%. Due to weak level of evidence and high heterogeneity found within reviewed studies, it is not possible to determine a robust recommendation as to what would be the best and safest feeding method and caloric progression protocol for patients at risk for developing RS.
A biological signal acquirer is attached to a subject and acquires a biological signal of the subject. A transmitter carried by the subject transmits the biological signal. A first communication port and a first camera are installed in a first location and connectable to a network. A second communication port and a second camera are installed in a second location and connectable to the network. A biological information acquiring device is connectable to the network and provided with a switcher. The switcher acquires, when communication establishment between the transmitter and the first communication port is detected, the biological signal through the first communication port as well as a first image taken by the first camera, and acquires, when communication establishment between the transmitter and the second communication port is detected, the biological signal through the second communication port as well as a second image taken by the second camera.
The invention relates to a cyclo-chromo-threo-valine-bright-leucine peptide (Trp-Thr-Val-Leu-Leu cyclic peptide) with hepatotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclotryptophan-threo-valine-leucine peptide is composed of tryptophan, threonine and valineLeucine and leucine, and pentadecane pentapeptide connected via amide bond. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure product of the cyclo-threo-valine-leucine peptide is white powder, and has half-Inhibitory Concentration (IC) on liver cancer cell HepG2  50  ) Comprises the following steps: 51.50. Mu.g/mL, half inhibitory concentration of alpha-glucosidase (IC)  50  ) Comprises the following steps: 140.81. Mu.g/mL. The compound can be used as a potential drug for treating liver cancer and weight loss.
The invention discloses application of grosvenor momordica fruit sweet essence to treatment of impaired glucose tolerance (IGT). The grosvenor momordica fruit sweet essence is prepared by extracting fresh grosvenor momordica fruit with hot water, curing proteins at high temperature, carrying out breaking and re-extraction, filtering obtained grosvenor momordica fruit tetracyclic triterpenoid extract with diatomite, then mixing the filtered product with modified starch, drying the mixture and grinding the dried mixture. The weight part ratio of the grosvenor momordica fruit tetracyclic triterpenoid drug substance to the modified starch is 1:(0.5-5). Spray drying and oven drying are carried out on the grosvenor momordica fruit tetracyclic triterpenoid drug substance and the modified starch, the dried substances are ground and sieved with a 60-mesh sieve and the powder is sub-packaged, 3g per package, thus preparing the grosvenor momordica fruit sweet essence. The grosvenor momordica fruit sweet essence is taken once 1-2 hours before lunch and 1-2 hours before supper respectively, 3g each time. 10 days is a course of treatment. The grosvenor momordica fruit sweet essence has the advantages that 1, the grosvenor momordica fruit sweet essence can be used for reducing the blood sugars of the persons suffering IGT and stopping the development towards diabetes mellitus; 2, the grosvenor momordica fruit sweet essence is practical and convenient and is low in treatment cost; and 3, the grosvenor momordica fruit sweet essence does not have any toxic or side effect.
Nearly 120,000 Veterans in care have cirrhosis, or advanced liver disease, from alcohol, hepatitis C, fatty liver disease, or other causes, and this number is rapidly increasing. There are life-saving measures that providers can take to prevent harm from cirrhosis. The three most impactful of these measures include providing access to post-discharge follow-up and screening for liver cancer and esophageal varices (veins that can cause catastrophic bleeding). However, only about one-third of Veterans receive care aligned with these three evidence-based practices (EBPs). Therefore, there is an urgent need to improve access to high-quality care for Veterans with this common condition.

By focusing on strategies that most successfully encourage implementation of evidence-based practices the investigators can address the urgent need to improve the quality and timeliness of care for Veterans with cirrhosis who receive care at VA hospitals. This quality improvement intervention seeks to understand which implementation strategies, or discrete activities that are conducted to promote EBP implementation, improve cirrhosis care. The aims of this evaluation are to: (1) empirically determine which combinations of implementation strategies ('data-driven strategies') are associated with the successful implementation of EBPs for Veterans with cirrhosis, (2) use Intervention Mapping to operationalize the 'data-driven' implementation strategies developed in the first aim, and (3) evaluate whether applying data-driven implementation strategies increases the use of EBPs for cirrhosis, using a hybrid type III stepped wedge cluster randomized trial. The investigators will measure cirrhosis care at all VA sites and use the data from aims 1 and 2 to provide feedback to all sites. The investigators anticipate that more intensive implementation interventions will directly impact 12 of the lowest-performing sites.
Dietary interventions represent an interesting alternative to pharmacological treatments for improving the quality of life (QoL) of subjects suffering from gastroesophageal reflux disease (GERD). This randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy of a food supplement (FS) containing a probiotic strain, bioactive peptides, and vitamins in relieving heartburn/dyspeptic symptoms in subjects with mild-to-moderate GERD. Fifty-six adult participants were randomly assigned to receive the placebo or the active FS for 28 days. Subjects were asked to record daily the frequency and intensity of heartburn episodes and the intake of over- the-counter (OTC) medications. GERD-QoL and self-assessment questionnaires were also completed every two weeks and at the end of the treatment, respectively. FS was effective in achieving a progressive and significant reduction of heartburn frequency and severity, with an intergroup significant difference at the end of the treatment period. FS group also reported a reduction in the OTC medication intake, whereas placebo administration did not modify the OTC intake. Results from the QoL and self-assessment questionnaires showed that FS administration achieved a progressive and statistically significant intragroup and intergroup improvement in the QoL score and a higher positive response with respect to the placebo treatment.
OBJECTIVE: Myostatin, which is known as a negative skeleton muscle regulator, is associated with mortality in maintenance hemodialysis patients. However, the significance of serum myostatin concentrations at dialysis initiation has not been established. We investigated the relation between serum myostatin concentrations and mortality or hospitalization within 1 year in incident dialysis patients.
METHODS: After a patient initiating hemodialysis or peritoneal dialysis during 2016-2018 was enrolled, the patient's serum myostatin at dialysis initiation was measured. Composite outcomes comprising mortality and hospitalization within 1 year after dialysis initiation were compared between two groups divided according to myostatin levels. The Cox proportional hazards model was used to assess significant relations between myostatin and outcomes.
RESULTS: This study examined 104 incident dialysis patients with a mean age of 65.5 ± 14.0 years (68% male). Kaplan-Meier analyses indicated the 1-year hospitalization-free and survival rate as significantly lower in the lower myostatin group than in the higher myostatin group (p = 0.0020). Cox proportional hazards regression analyses revealed that the value of myostatin logarithm at dialysis initiation was inversely associated with the occurrence of a composite outcome, independently of age (hazard ratio 0.16, 95% confidence interval: 0.05-0.57). Receiver operating characteristic analysis showed the area under the curve of serum myostatin for predicting death or hospitalization within 1 year as higher than those of clinical indices of nutritional disturbance and frailty.
CONCLUSION: Serum myostatin concentration at dialysis initiation is inversely associated with adverse outcomes in these dialysis-initiated patients.